Abstract 530P
Background
Current comprehension of micropapillary lung adenocarcinoma (MP-LUAD) remains circumscribed to the realms of biological behaviors and genomic landscapes. Previous studies from our institute have shown that there exist subtle and unactionable genomic alterations between MP and non-MP early-stage lung adenocarcinoma (LUAD). Therefore, deciphering the unknown non-genomic regulatory network of MP-pattern malignancy may offer opportunities to uncover more tractable therapeutic targets for MP-LUAD patients.
Methods
A retrospective cohort of 66 surgical specimens from early-stage LUAD, including MP and other histologic subtypes, was mapped as discovery and validation cohorts. High-throughput screening was performed on cryosectioned and microscopically laser capture microdissected paired micropapillary and Acinar LUAD tissue. In vitro and in vivo experiments for validation were performed using co-culture of tumor associated macrophages (TAM) and tumor cells, xenograft mice and zebrafish models. ChIP-seq, CUT&Tag-seq and RNase I-PCR were employed to profile aberrant histone modifications, transcription factor occupying and chromatin accessibility in MP-LUAD.
Results
Bulk RNA-seq after microdissection showed aberrant activation of the MYC pathway in MP. MYC overexpression fostered MP-pattern malignancy of tumor tissue in immunocompetent mice, but not in vitro. Through screening via single-cell RNA-seq, retrospective cohort, and TCGA dataset, we found aberrant accumulation of TAMs around MP tissues. in vitro co-culture and in vivo dependency experiments demonstrated that MYC overexpression in tumor cells exhibited a MP-pattern malignancy in collaboration with TAMs. Follow-up experiments revealed that, MYC interacted with the pioneer transcription factor FOSL2 induced by TGFβ secreted from TAMs, aberrantly accessible chromatin, and induced epigenetic reprogramming of MP-pattern gene transcription.
Conclusions
Our study uncovered copy number amplification-induced activation of MYC in MP-LUAD, which by recruiting TAMs, cooperatively transcriptionally regulates MP pattern genes and promotes a metastatic malignancy.
Clinical trial identification
Editorial acknowledgement
We gratefully acknowledge all members of the Jiangsu Cancer Hospital Biobank and Department of Pathology for collection and storage of surgical samples used in this study. We gratefully acknowledge Ms. Luyuan Pan and Ms. Linglu Li from the China Zebrafish Resource Center for providing wild-type AB-line zebrafish and assistance with zebrafish-based experiments. We gratefully acknowledge instructions and guidance on DNase I-PCR experiments from Lu Wang Lab, Northwest University. We gratefully acknowledge plasmids from Wafik El-Deiry Lab and Andrea Califano Lab.
Legal entity responsible for the study
Nanjing Medical University Affiliated Cancer Hospital.
Funding
National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study
Presenter: Myung-Ju Ahn
Session: Poster Display
Resources:
Abstract
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract